Week Ending May 9, 2022

Review Outlines Advancements in Precision Therapy for Metastatic Lung Cancer
“In a new review published in The American Journal of the Medical Sciences, researchers outlined how targeted therapies and personalized medicine offer potential in redefining molecular lung cancer care.”

Clinical Chest Images Power Up Survival Prediction in Lung Cancer
“In patients with stage I lung cancer, adding noncancerous features from CT chest imaging predicts overall survival better than clinical characteristics alone, according to a paper published online in the American Journal of Roentgenology.”

Dr Anne Chiang Discusses Considerations in SCLC Treatment: Benefits vs Side Effects, and Quality of Life
“Anne Chiang, MD, PhD, is an associate professor of medicine in the Section of Medical Oncology at Yale School of Medicine, specializing in thoracic oncology, with a background in translational research in metastasis; she has extensive experience in clinical practice in both academic and community settings. In addition, Chiang is the deputy chief medical officer and chief integration officer for Smilow Cancer Hospital, where she has helped build the SCH Network and spearhead both quality initiatives as well as clinical research.”

Is There a Vaccine for Lung Cancer?
“Cancer vaccines may sound like science fiction, but they already exist. Some vaccines, like the human papillomavirus (HPV) vaccine, can prevent cancer. Other types of vaccines help treat cancer.”

VA Medical Center Uses New Robotic Arm to Diagnose Lung Cancer in Veterans
“A new robotic member of the Thoracic Oncology program is lending a hand to diagnose and treat lung cancer patients at the Washington DC VA Medical Center.”

Delfi Diagnostics Initiates 15,000-Patient Prospective Lung Cancer Screening Trial
“Delfi Diagnostics, a pioneering developer of next generation high performance, affordable liquid biopsy tests for early cancer detection, has enrolled the first participants in the CASCADE-LUNG study. CASCADE-LUNG is a prospective, multi-center trial that will enroll up to 15,000 participants at the time of their low dose CT (LDCT) lung cancer screening and will add to the clinical validation of Delfi’s liquid biopsy test for lung cancer detection.”

Role of Immunotherapy in Newly Diagnosed NSCLC